Medicaid Managed Care Open Enrollment Extended through Dec. 15
Current Suspected Overdose Deaths in Delaware for 2017: 225
Rita Landgraf, Secretary
Jill Fredel, Director of Communications
302-255-9047, Pager 302-357-7498
Date: March 19, 2013
The Delaware Division of Public Health is reviewing a drug recall today to determine if Delaware received any of the recalled product from Med Prep Consulting Inc. of Tinton Falls, N.J. Med Prep is voluntarily recalling all lots of products compounded at its facility. The recall is targeted at medical providers, including hospital pharmacies and related departments, and physicians' offices.
The recall resulted from the pharmacy being notified by a Connecticut hospital that it observed visible particulate contaminants in 50 ml bags of Magnesium Sulfate intravenous solution that were confirmed to be mold. In an abundance of caution, the pharmacy included all compounded products in the voluntary recall due to lack of sterility assurance. Although administration of an intravenous product found to be contaminated with mold could result in a fatal infection, it is uncertain whether the mold found in these products can cause illness in humans.
"DPH is working with our partners in New Jersey and the FDA to determine if any recalled products were shipped to Delaware," said Dr. Karyl Rattay, DPH director. "If any products were shipped to medical facilities in the state, DPH staff will be contacting each facility and instructing how to dispose of the product. In the event recalled products were used, DPH will be working with medical facilities to monitor patients."
Additional information to follow Wednesday, March 20, 2013.
Delaware Health and Social Services is committed to improving the quality of the lives of Delaware's citizens by promoting health and well-being, fostering self-sufficiency, and protecting vulnerable populations.